Novo Nordisk shareholders have filed a lawsuit alleging that the company misled investors regarding key aspects of a clinical trial for its next-generation weight-loss drug, CagriSema. On Tuesday, a U.S. federal judge allowed parts of the lawsuit to proceed, finding that investors had plausibly alleged that certain statements about CagriSema's tolerability and the design of its late-stage trial may have been misleading. The ruling does not determine Novo Nordisk's liability for securities fraud but permits the case to advance to the evidence-gathering stage, where investors can seek to substantiate their claims [1].
The lawsuit centers on the REDEFINE-1 study for CagriSema, an experimental weekly injection combining semaglutide (the active ingredient in Wegovy and Ozempic) with cagrilintide. When Novo Nordisk released topline results in December 2024, investors had expected average weight loss of about 25%, but the company reported an average weight loss of approximately 20.4%, which led to a sharp decline in the company's stock price. Shareholders argue they were not adequately informed that the REDEFINE-1 study used a flexible dosing approach, allowing participants to adjust their doses rather than requiring escalation to the maximum level. Only 57% of participants reached the highest dose. Investors also allege that Novo Nordisk gave the impression that the Phase 3 trial would use a fixed maintenance dose, as in earlier trials, which was not the case [1].
The distinction in dosing approach is significant because it affects the interpretation of the trial's results, particularly regarding drug tolerability at the highest dose. The court noted that the ability of patients to remain on the intended dose is a key issue for obesity medicines. Judge Robert Kirsch emphasized that while clinical trials are complex, pharmaceutical companies must not mischaracterize or omit important aspects of such trials in a misleading way [1].
Novo Nordisk has stated that it believes the allegations are meritless and intends to vigorously defend against them. The lawsuit comes at a time when Novo Nordisk is working to bolster investor confidence in its obesity business amid increasing competition from Eli Lilly and as it invests heavily in next-generation weight-loss treatments [1].
CONCLUSION
The lawsuit against Novo Nordisk highlights investor concerns over transparency in clinical trial disclosures for its key obesity drug candidate, CagriSema. With the case moving forward, Novo faces heightened scrutiny as it seeks to maintain its competitive edge in the rapidly evolving weight-loss drug market.